SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Vigil Neuroscience, Inc. (Nasdaq – VIGL)
BALA CYNWYD – June 4, 2025/Globe Newswire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Vigil Neuroscience, Inc. (“Vigil” or the “Company”) (Nasdaq – VIGL) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Sanofi (Nasdaq – SNY). Under the terms of the transaction, Sanofi will acquire all the outstanding shares of Vigil for an upfront payment of $8.00 per share of common stock in cash. Vigil shareholders will also receive a non-tradeable contingent value right (CVR) entitling the holder to potentially receive an additional $2.00 per share in cash payable following the first commercial sale of VG-3927 if achieved within a specific period. The total equity value of the transaction, including the potential CVR payment, represents approximately $600 million on a fully diluted basis.
The investigation concerns whether the Vigil Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the consideration provides fair value to the Company’s shareholders.
If you own shares of Vigil stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman by email at clients@brodsky-smith.com, or call toll free 855-576-4847.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.